According to new data, a Covid vaccine contract that was cancelled by the UK government cost taxpayers £358.6 million.
Valneva, a French company, had planned to produce more than 100 million vaccines at its West Lothian facility, but the agreement was contentiously terminated in 2021.
Valneva has received non-refundable payments totaling hundreds of millions of pounds, according to financial documents filed by the company.
With Valneva, the UK government reached a final settlement last year, and the company is no longer owed any money.
At the time, ministers declared that all additional information regarding this resolution was commercially confidential.
The Almeida plant in Livingston, which Valneva built to produce the Covid vaccine, is currently being considered for sale, according to the company. .
In September 2021, the UK government cancelled its vaccine agreement with Valneva over claims of a breach of the contract, which the biotech company "strenuously denied.".
A filing made to the United States government agency, the Securities and Exchange Commission, contains information about the amount the UK government paid to Valneva.
According to the document, Valneva's vaccine supply contract with the UK government netted the company a total of €420.6m (£358.6m).
This is broken down as €47.5m (£40.5m) in a "settlement agreement" following the deal's termination; €78m (£66.5m) in capital expenditure; and the remaining amount in non-refundable payments for manufacturing costs.
The nationwide rollout of Covid vaccines, according to previous statements from the UK government, was unaffected by the cancellation of the Valneva deal.
In Livingston, Valneva employs about 190 people. The potential sale of the idle Almeida plant has no impact on the company's current operations in the town.
The French company has now hired a commercial real estate company to investigate options for the 75,000 square foot facility, which was constructed to the exacting technical specifications required to manufacture vaccines.
Thomas Lingelbach, the chief executive of Valneva, told Bloomberg News last month that the site had attracted the interest of about a dozen potential buyers.
The French company was required to pay back £69.8m of the advances it had received from the UK government under the terms of the original agreement between Valneva and the government of that country in the event that the Almeida plant was sold or used for a purpose other than producing Covid vaccines.
This obligation passed away on December 31st of last year, according to Valneva's financial statement.
Scottish Enterprise gave Valneva grants worth up to £20 million last year to support its development of new vaccines and continued growth.
The economic development agency for Scotland has provided a total of £4.3 million in assistance.
According to a Valneva spokesman, the company is "exploring options for its Almeida manufacturing facility in Livingston, which was originally built to produce its Covid-19 vaccine, including a possible sale or repurposing to produce its vaccine for Japanese encephalitis and its chikungunya vaccine, if approved."
